Release Summary

DARA BioSciences, a specialty pharmaceutical company, announced today that on February 12, 2013, NASDAQ notified DARA that it has regained compliance with NASDAQ's $1.00 Minimum Bid Price Rule.

DARA BioSciences, Inc.